Prescription drug legislation currently before the House is unfair to drug manufacturers. Many experimental drugs are costly to develop. New rules further limiting duration of patents and setting price ceilings would discourage pharmaceutical companies from developing new drugs. The United States' role as the world's leading producer of new drug technology is a direct result of a free market economy. Please consider the welfare of sick Americans and the need for new drug development when you vote on H.R. 1310.
